Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Danaher; PrimeraDx; Institute for Animal Health

NEW YORK (GenomeWeb News) – Danaher's board of directors has declared a quarterly dividend of $.025 per share. The dividend is payable on Oct. 26 to all shareholders of record on Sept. 28.


PrimeraDx has received the CE Mark for its ICEPlex system and C. difficile detection assay. The ICEPlex is a quantitative multiplex PCR system.

"Obtaining the CE mark on our instrument and assay is an important step in the process of global commercialization of our extensive pipeline of molecular diagnostics products in infectious disease and oncology … and demonstrates to current and future customers, and strategic partners, our ability to develop and support high-quality diagnostic products," PrimeraDx CEO Matt McManus said in a statement.


The Institute for Animal Health in the UK will change its name to The Pirbright Institute, effective Oct. 4, the Biotechnology and Biological Sciences Research Council said this week.

"The new identity, as The Pirbright Institute, represents the coming together of institute science on a single site, the strength of the new science strategy and is a sign of the bright future for Pirbright with over £250M of investment committed to the institute in the coming years," BBSRC Chief Executive Douglas Kell said in a statement.

The Pirbright Institute receives strategic funding from BBSRC and the council is the institute's corporate trustee director.


In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.